GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptorum Group Ltd (NAS:APM) » Definitions » Insider Ownership

Aptorum Group (Aptorum Group) Insider Ownership : 0.00 % (As of Apr. 29, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Aptorum Group Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Aptorum Group's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Aptorum Group's Institutional Ownership is 0.76%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Aptorum Group's Float Percentage Of Total Shares Outstanding is 55.88%.


Aptorum Group Insider Ownership Historical Data

The historical data trend for Aptorum Group's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptorum Group Insider Ownership Chart

Aptorum Group Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Insider Ownership
Get a 7-Day Free Trial - - - - -

Aptorum Group Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Insider Ownership Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Aptorum Group Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.


Aptorum Group (Aptorum Group) Business Description

Traded in Other Exchanges
N/A
Address
17 Hanover Square, London, GBR, W1S 1BN
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.